Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Tempus AI, Inc.
TEM
NASDAQ·Healthcare·Medical - Healthcare Information Services·Mkt cap $10.8B
$60.27
▼ -2.16%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$41.73 - $104.32
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 4.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary AI-driven data analytics
- Extensive clinical and molecular data library
- Strategic pharmaceutical partnerships
- Advanced machine learning algorithms
Bear Case
2 risks
- Very high volatility (beta 3.6). Expect 3x market swings. Position size accordingly.
- Growth premium of 0.0x vs Healthcare IT & Services peers. Reasonable for this growth rate.
Growth
Moderate growth ahead
Increasing precision medicine adoption
Value
Growth premium of 0.0x vs Healthcare IT & Services peers. Reasonable for this growth rate.
Momentum
Hot
+30.0% over 3m
Quality
Excellent
High-growth business (70% revenue growth, 70% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying TEM right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 4, 2026
MAY 5, 2026
Reported EPS of -$0.13 vs -$0.21 consensus (+38.1% surprise). Revenue of $348.1M vs $345.4M expected (+0.8%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+38.1%
Next: May 4, 2026
Revenue trend · last 8Q
—
—
+36%
+75%
+90%
+85%
+83%
+36%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$166.0M
$180.9M
$200.7M
$255.7M
$314.6M
$334.2M
$367.2M
$348.1M
Margins · last 8Q
Gross
—
Operating
—
Profit
-36.2%
Wall Street consensus
7 analysts · 86% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
86%
Hold
14%
Sell
0%
Median Price Target
$72.00
▲ +19.5% vs $60.27
Latest: Needham · Jun 1, 2026
2 analysts covering